Historical Newspapers of South Carolina

Below is the OCR text representation for this newspapers page. It is also available as plain text as well as XML.

I Skilling tells panel he didn’t lie PHOTO BY CHUCK KENNEDY/KRT CAMPUS £nron Vice President of Corporate Development Sherron Watkins, former Enron CEO Jeffrey Skilling and Jeffrey McMahon are sworn in on Capitol Hill on Tuesday before testifying before the Senate Commerce Committee hearing on Enron. BY H. JOSEF HEBERT THE ASSOCIATED PRESS WASHINGTON - Former Enron chief executive Jeffrey Skilling, at times combative, in sisted Tuesday he knew nothing about manipulation of company books and denied misleading Congress as some lawmakers and Enron officials have alleged. “I have not lied to Congress or anyone else,” declared Skilling at a five-hour Senate appearance. He aggressively defended the ac tions he took as Enron’s chief ex ecutive while cashing in $66 mil lion of company stock. Several senators were openly skeptical. “I don’t believe you when you say you didn’t know what was go ing on,” said Barbara Boxer, D CalifTShe engaged Skilling in a heated exchange over his sale of Enron stock at time that he was urging employees to buy as much as possible. He resigned last August about the time that an Enron vice pres ident, Sherron Watkins, was warning chairman Kenneth Lay the company’s financial dealings could cause it to “implode in a wave of accounting scandals.” Watkins, for the first time sharing the witness table with Skilling, told the Senate Commerce Committee on Tuesday that she had no doubt he was aware of the problems posed by Enron’s use of partnerships that were largely financed by com pany stock, contrary to normal ac counting practices. Sharply disputing Watkins’ tes timony earlier this month, Skilling denied he had misled Lay, the longtime Enron chairman who recently resigned. Lay has de clined to testify. “I never duped Ken Lay,” said Skilling, using Watkins’ wording. Watkins characterized Lay in harsher terms than she had at the House hearing, when she painted a picture of a chairman largely out of the loop. She said Tuesday the investi gation he ordered produced “a whitewashed report,” and she said she was “incredibly frustrated” when Lay last October failed to move aggressively to take actions to protect the company. “I believe that Enron had a brief window to salvage itself... and we missed that opportunity because of Mr. Lay’s failure to rec ognize or accept that the compa ny had manipulated its financial statements,” Watkins said. Millions of investors lost mon ey, and thousands of current and former Enron employees lost the great bulk of their retirement sav ings when the company collapsed. Skilling said he was aware of the partnerships but relied on as surances from Enron’s accoun tants that the structures were proper. “I am not an accountant,” he said, adding that he felt com fortable with the arrangements. He disputed suggestions from several lawmakers that he had been warned of the precarious na ture of Enron’s partnerships and possible conflicts of interest. He said he now believes “there may have been self dealing by a small number of executives.” Skilling said he was unaware that Fastow, who created some of the key partnerships, had made $30 million off them and that sev eral other executives had en riched themselves by the off-the books dealings. “I believe Mr. Andy Fastow would not have put his hands in the Enron candy jar without an ex-' plicit or implicit approval to do so by Mr. Skilling,” Watkins insisted. —1 11 i—i i (Contraceptive Injection &lrtK con-troi you-tkir^ a&ou-t jus-t +*ayear medroxyprogesterone acetate injectable suspension DEPO-PROVERA Contraceptive Injection (medroxyprogesterone acetate injectable suspension, USP) This product is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted diseases. What is DEPO-PROVERA Contraceptive Injection? DEPOWOVERA Contraceptive Injection ii a form of birth control that is given as an •ntramusoiar sr-jedicri (a shot) m the buttock or upper arm once every 3 months (13 weeks). To continue your .cotraceptive protection, you must return for your next injection promptly at the end of 3 months (13 weeks) DEKYPROVEPA contains meJroxypi-cgesterone acetate, a ,i >,milar to (but riot the same as) the natural hormone progesterone, which is produced by yosr ovaries during the second half of your menstruai cycle. DEPO-PROVERA acts by preventing your egg ceSs from npen-nc. if an egg is not released from the ovaries durng your nwistruai cyce. t cannot become ferried by sperm and result r> pregnancy. DEPO-PRuvtRA aHo causes dwiges in ;he fining of your uterus that make it less trkeiy for pregnancy to occur How effective is DEPO-PROVERA Contraceptive Injection? The efficacy of DEPO-PROVERA Contraceptive Injection depends on following the recommended dosage schedule exactly (see "How often do I get. my shot of DEPO-PROVERA Contraceptive Injection?") To make sire you are not pregnant when you first get DCPO-PRQVfRA Contraceptive l^icction. you* tVst injection must be give ONLY during the first 5 dars of a no-maf menstrual period; ONLY wrtnm tlie first 5 days after childbrnh if not breast-feeding a f exclusively breast-feeding. ONLY at the sixth week after childbirth, fit is a forw-teim injectable contraceptive when administered at 3-month (13-weex) intervals. DEPO PRDv'tRA Contraceptive Injection is over 99% effective, making it one of tf* most reliable methods ofb-rt^ control available. This means that the average annual pnegnaney rate is less than one for every 100 women who use DEPO-PROVERA The eifectrveness of most contraceptive methods depends in part on how reliably each woman uses the method The effectiveness of DEPO-PROVERA depends only on tfm patient »etumng every 3 months (13 weeks) for fier next idjectior. You- i >ea»r.-care provider win help you compare DEPO-PROVERA. with other rontiaceptive methods and give you the information you need in order to decide which w contrcceotive method is the right choice for you The fofiovxng table shows the percent of women who got pregnant while usn* different kinds of contraceptive methods. H gives both the. lowest expected rate ot pregnancy (the rate expected <n women who use each method exactly as it should be used! and the typical rate of pregnancy (wfveh mciudes women who became pregnant because they forgot to use their birth control or because they did not fofiew the directions exactly). Percent of Women Experiencing an Accidental Pregnancy in the First Year of Continuous Use Lowest Method__Expectedtypical i. vuii _0£20.2* fc-maie startoaon _ _ 0.2 0-i HA sttriuJk-*,CXI Oral ewtraCBpiive (i;#j 3 Comtaned - 0.1 FropMOiyn on»y 0J> _____ ..nib .# • i. fYogcsuwrt- 2.0 _CopperT 38QA_ j__'_08___-_ Ccodun (AtStxxX sperrmadr} _2 _-_111 L!iapttf.i£'i! 'wrfll-vpwmide) _4IB ' ■--<•• *!(<{>*>IB Withdrawal_ 418_ Piniptik ittrsinxyKj; __ __1-9__ 2ft_ Sjymxfcjy .ikyie 3 21 Vifinit Spurge teed before ciaWbirth. 6 18 uy»d'after diUdbrtti ^ _* 9_28 .. „ _£__£ Soukv inijvefl cl & Obstei Gpiecol l99(X7£kS58- S67. "I mm Norfiwiie package insert Who should not use DEPO-PROVERA Contraceptive Injection? Not ** women should use DEPO-PROVERA. You should not use DEPO-PROVERA if you fave a y of the foifowirig conditions: • if you think you might be pregnant • if you have any vaginal Weeding without a known reason • if you have had cancer of the breast • if you have had a stroke • >f you have or have had Wood clots (phtebitis) in your legs • if you have problems with your fiver or liver disease 1 • if you are allerg*r. to DEPO-PROVERA (medroxyprogesterone acetate or any of its other ingredients). ' What other things should I consider before using DEPO-PROVERA ' Contraceptive Injection? You will lave a physical examination before your doctor prescribes DEPO-PROVERA. ft is ■ important to tell your health-care provider if you have any of the following: • a family history of beast cancer • an abnormal mammogram (breast x-ray), fibrocystic breast disease, beast nodules oc lumps, or Weeding from your nippies • kidney disease • h regular or scanty menstrual periods • high blood pressure • migraine tseadaches • asthma • epilepsy (convulsions or seizures) • diabetes or a farrufy history of dsafcietes • a history of depression • if you are taking any prescription or over-the-counter medications This product is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis. What if I want to become pregnant after using DEPO-PROVERA Contraceptive Injection? Because DEPO-PROVERA «s a long-acting birth control method, it takes some time after your last injection hr its effect to wear off Based on the results from a large study done in the United States, for women who stop using DEPO-PRCVERA in order to become pregnant, it is expected that about half of those who become pregnant will do so in about 10 months after thesr last injection, about two th=rd$ of those who become pregnant w# do so in about 12 months; about 83% of those who become pregnant wrf do so in about 15 months; and about 93% of tfrose who become pregnant w® do so in about 18 months after the#- Iasi injection. The length of time you use DERDPRGVERA has no effect on how ky^it takes you to become preananr after you stop uwng it What are the risks of using DEPO-PROVERA Contraceptive Injection? 1 irregufur Menstntof Bfeecfc* The ude effect reported most frequently by women who use DEPO-PROVERA for contraception is a change m their rxxmal menstrual cycle. Owing the first year of using DEPO-PROVERA, you might have one or more of the following changes, irregular or unpredictable bleeding or spotting, an increase cx decrease m menstrual bleeding, or no speeding at all UiusuaSy heavy or continuous bfeesfing,however, is not a usual effect of DtPO-PROVERA; and if this happens, you should see your health-care provider right away. With continued use of DEPO-PROVERA. Weeding usually decmases, and many women stop having periods completely In clinical studies of DEPO-PROVERA. 55% of the women studied reported no menstrual Weeding (amenorrhea) after i year of use. and 68% of Use women studied reported no menstrual bleeding after 2 years of use. The reason that your periods stop is because DEPO-PROVERA causes a nesting state in your ovanes. When your ovaries do not release an egg monthly, the regular monthly growth of the lining of your uterus does not occur and, therefore, the bleeding that comes with your normal menstruation does not take place When you stop using DEPC-PROVERAyour menstrual period will usually, m urne. return to its normal cycle. 2 Bene Mineral Changes Use of DEPO-PROVERA may be associated with a decrease in the amount of mineral stored =n eur bories. 1>n* could increase your risk of developing bone fractures. The rate of bone mineral s is greatest in ihc early years of DEPO-PROVERA use. but after that it begins to resemble the normal rate of age-related bone mineral loss. ICorttf Studies of women 'who have used different, forms of contraception found that women who used DEPO-PROVERA for contraception had no increased overall ride of developing cancer of the breast ovary, uterus, cervix, cr fiver However women under 35 years of age wftosc first exposure to DEPO-PROVERA was within the previous 4 to 5 years may have a slightly increased risk of developing breast cancer similar to that seen with oral contraceptives. You should discuss this with your health-care provider ^-Unexpected Pregnancy Because DEPO-PROvERA is such an effective contraceptive method, the risk of accidental pregnancy for women who get their shots regularly {every 3 months [ 13 weeks)) is very low. While tlieie tiave been reports of an increased nsk of tow birth wisgfit and neonatal infant death o»’'Other health problems in infants conceived close to flie time of injection, sucti pregranoes are uncommon If you flank, yog may have become pregnant while using DEPQ-PnOVERA for contraception, see your heafth-canp prowler as soon as possible. SASergc Reactions Some women usng DEPO-PROVERA Contraceptive injection have reported severe and S“ life-threatening allergic reactions known as anaphylaxis and anaphylactoid reactions < include the sudden onset of hives cx swefeog and itching of the skin, breathing 1 and a drop in Wood pressure. .Other Risks Vomen who use hormone-based •contraceptives may have an increased risk of blood dots or troke. AHo. if a contraceptive method fails, there <s a possibility that the fcrttSzed egg wiBbegm ? develop outside of the uterus (ectopic pregnancy). Whie these events are rare, you shotid HI your health-care provider if you have any of the problems listed in the next section. Vhat symptoms may signal problems while using DEPO-PROVERA Contraceptive Injection? [ail your health-care provider immediately if any of these problems occur following an infection f DEPO-PROVERA: sharp chest pan. coughing up of Wood, or rudden shortness of breath (indicating a possible clot in the lung) sudden severe headache or vomicng, dizziness or fainting, problems with your eyeaght or speech, weakness, or numbness « an arm or ieg (indicating a possible stroke) severe pain or swe&ne in the calf (indicating a possible dot in the fog) unusually heavy vaginal bleeding severe pan or tenderness m the lower abdomiral area pervstera pain, pus. or Weeding at the injection site Vhat are the possible side [effects of DEPO-PROVERA Contraceptive Injection? .Weight Gain ou may experience a weightream while you are using DEPO-PROVERA. About two thirds of se women who used DEPO-PROVERA in cNnical trials reported a weigtrt gain of about 5 pounds unng the first year of use. You may continue to gain weight after the fast year Women m one irge study who used DEPO-PROVERA for 2 years gamed .in average total of 8.1 pounds over x*se 2 years, oi- approximately 4 pounds per year Wbmen who continued for 4 years gamed an verage total of 13-8 pounds over those 4 years, or approximately 3.5 pounds per year Women /ho continued for 6 years gained an average total of 165 pounds over those 6 years, or pproximateiv 175 pounds per year. Other Sxfc Effects i a clinical study of over 3.900 women who used DEPO-PROVERA for up to 7 years, some /omen reported the foiicwng effects that may or may not have been related to their use of jEPO-PROVERA: irregiiai- menstruaf bleeding, amenonhea. headache, nervousness, abdominal ramps, dizzir-efs. weakness or fatigue, decreased sexi/al des*«. leg Damps nausea, vaginal rscharge or irritation, breast swelling and tenderness. teoatmg, swelling of the funds or feet ackaehe, depression, insomnia. acne, pelvic pairs, no hair growth or e*<ess/ve hair loss. rash, hot ashes, and joint pain Ottier problems were reported by very lew of tfse women in the dinrcal nats, but some of these could be senous. These include convulsions, jaundice, urinary tract Sections. allergic reaction, feinting, paralysis, osteoporosis, lack of return to fertility, deep vein vomboss. P'Jmonary emboius. breast cancer, or cervical cancer if these or any od«r probferre ccur dunng your use of DEPO-PROVERA. discuss them with your tiealth-care provider ihould any precautions be followed during use of DEPO-PROVERA Contraceptive Injection? Ateseci Periods Xrmo the time you are using DCPO-PRCVERA for contraception, youmay slop a period, or your enock may stop completely. If you have been receiving your DEPO-PROVERA injections ?gular!y every 3 months (i 3 weeks), then you are probably not pregnant. However, if you think sat you may be pregnant, see your health-care provider Lolmit&Y'ksi Interactions you are scheduled for any laboratory tests, tell your health-care provider that you are using JEPO-PROVERA for contraception Certain blood tests are affected by hormones such as JEPO-PROVERA. Slntenxoons ■ en (ammogiutethmvete) is an anti cancer drug that may significantly decrease the eness of DEPO-PROVERA if the two drugs are given during the same time. S Mothers DEPO-PROVERA can be passed to the nursing infant in the breast mtik. no harmful ve been found « tNrse ch--ldren. DEPO-PROVERA does not p»event the b« easts from roduor*; milk, so t can be uved by nursing mothers. However, to rrmimue the amount of JEPO-PROVERA that is passed to the infant in the first weeks after fcflh, you shoukj wait until weeks after chdbhiith before you start using DEPO- PROVf RA for contraception, low often do I get my shot of DEPO-PROVERA Contraceptive injection? he recommended dose of DEPO-PROVERA s 150 mg eveiy 3 monttss (i 3 weeks) given m a ingle intramuscular injection m the buttock or upper arm. To make sure that you an? not pregnant t the tiros of the fu st Injection, it ir, essentia! that the injection be given ONLY during the first days of a normal menstrual penod. If used fbSowmg the delivery of a child, the first injection of JEPO-PROVERA MUST be grven within 5 days after childbirth if you are rot breast'feedmg or . weeks after childbirth if you are exclusively breast-feeding. If you wait longer than 3 months 13 weeks) between injections, or longer than 6 weeks after delivery, yeer tealth-care prowder houtd determine tfwt you are not pregnant before gjvtng you your injection of DEPO-PROVERA. lx only CB-7-S Pharmacia harmacia & Upjohn Company StUpjohn " Whaley's Mill Apartments Est. 1895 - A tdacHtwrv a£lrfi& Ca/LfAntb. $ A. ► A premiere location (walking distance to USC) I Fully furnished apartments I USC Shuttle service to campus I Swimming pool ► Computer lab I Free movie rentals I Social activities I Friendly management team I Flexible leases available I 1,2,3, and 4 bedroom apartment Tours available now to improve your standard of living 803.254.7801 ' _l_ l _ _I ■ i■ .... — — i ■ ii-___ _ __ . . , i*b**|I***«,|p*p!